Clinical trials: Progressive Glioblastoma Multiforme
Glioblastoma Multiforme, Astrocytoma
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.
- Trial name
- NCT00154375
- Testing
- Imatinib mesylate, Hydroxyurea
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Glioblastoma
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03679754
- Testing
- Ad-RTS-hIL-12, veledimex
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive…
- Trial name
- NCT06061809
- Testing
- Bevacizumab, PD-L1 t-haNK, N-803
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- ImmunityBio, Inc.
Brain and Central Nervous System Tumors
Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for glioblastoma multiforme and anaplastic astrocytoma.
- Trial name
- NCT00052624
- Testing
- transferrin-CRM107
- Where
- 2 sites in United States
- Sponsor
- Xenova Biomedix
Glioblastoma Multiforme, Glioma
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors.
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02502708
- Testing
- Indoximod, Temozolomide, Conformal Radiation
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- NewLink Genetics Corporation
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Glioblastoma, Glioblastoma Multiforme
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
- Trial name
- 105GM201 (NCT01564914)
- Testing
- TRC105, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Recurrent or Progressive Malignant Glioma
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma.
- Trial name
- NCT00539344
- Testing
- ANG1005
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Angiochem Inc
Glioblastoma
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
Glioblastoma (GBM) comprises about 16% of all malignancies of the nervous system and over 50% of all gliomas. Standard of care for newly-diagnosed GBM is a combination of surgical debulking followed by concurrent radiotherapy and…
- Trial name
- NCT02876003
- Testing
- G-202
- Where
- United States
- Sponsor
- GenSpera, Inc.
Glioblastoma Multiforme of Brain
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the…
- Trial name
- NCT05627323
- Testing
- CHM-1101 CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Chimeric Therapeutics
Glioblastoma, Adult
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
- Trial name
- ROSALIE (NCT04116658)
- Testing
- Multiple dose of EO2401
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 100 people
- Sponsor
- Enterome
Glioblastoma
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human interleukin-12 (IL-12).
- Trial name
- NCT03636477
- Testing
- Ad-RTS-hIL-12, veledimex, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Alaunos Therapeutics